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Human babesiosis is an emerging tick-borne infectious disease caused by intraerythrocytic protozoan species of the genus Babesia
with many clinical features similar to those of malaria. Over the last 50 years, the epidemiology of human babesiosis has changed
from a few isolated cases to the establishment of endemic areas in the northeastern and midwestern United States. Episodic
cases are reported in Europe, Asia, Africa, and South America. The severity of infection ranges from asymptomatic infection
to fulminant disease resulting in death, although the majority of healthy adults experience a mild-to-moderate illness. People
over the age of 50 years and immunocompromised individuals are at the highest risk of severe disease, including those with
malignancy, HIV, lacking a spleen, or receiving immunosuppressive drugs. Asymptomatic carriers present a blood safety risk when
they donate blood. Deﬁnitive diagnosis of babesial infection generally is made by microscopic identiﬁcation of the organism on
thin blood smear, ampliﬁcation of Babesia DNA using PCR, and detection of Babesia antibody in acute and convalescent sera.
Speciﬁc antimicrobial therapy consists of atovaquone and azithromycin or clindamycin and quinine. Exchange transfusion is used
in severe cases. The use of multiple prevention strategies is recommended and consists of personal, residential, and community
approaches.
Copyright © 2009 E. Vannier and P. J. Krause. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Human babesiosis is an emerging tick-borne infectious
disease caused by an intraerythrocytic protozoan and has
many clinical features similar to those of malaria. The
parasite was ﬁrst described in cattle by Babes in 1888 [1].
The ﬁrst human case was described in 1957 [2]. Over the
past 50 years, the epidemiology of the disease has changed
from a few isolated cases to the establishment of endemic
areas in southern New England, New York, New Jersey, and
the northern Midwest [3–8]. Isolated cases are reported
o v e raw i d eg e o g r a p h i cr a n g ei nE u r o p e ,A s i a ,A f r i c a ,a n d
South America [9–17]. We will review the epidemiology,
clinicalcharacteristics,diagnosis,andtreatmentofinfections
caused by the four Babesia species that most commonly
infect people: B. microti, B. duncani, B. divergens,a n dB.
venatorum.
2. Epidemiology
2.1. United States
2.1.1. B. microti Infection. The most common cause of
human babesiosis is Babesia microti,aBabesia of mice and
other small rodents that is endemic in the United States
[5–8]. Most cases occur along the northeastern seaboard.
The ﬁrst conﬁrmed case was a normosplenic individual
on Nantucket Island oﬀ the coast of Massachusetts [18].
Additional cases were soon identiﬁed and the disease became
known as Nantucket fever. Other islands oﬀ the coast of
southern New England subsequently became recognized as
endemic areas, including Martha’s Vineyard, the Elizabeth
Islands, Block Island, Shelter Island, the eastern part of
Long Island, and Fire Island [19]. Endemic areas on the
mainland include Cape Cod, the southwestern counties of
Rhode Island, and southeastern Connecticut [6, 19, 20].2 Interdisciplinary Perspectives on Infectious Diseases
Babesiosis has been diagnosed in individuals from the
Lower Hudson Valley (Westchester, Putnam, Dutchess, and
Columbia counties) in New York State, and is endemic in
New Jersey [21–23]. B. microti is also the etiologic agent
of babesiosis in the northern midwestern region of the
United States, particularly in Wisconsin and Minnesota [24–
26]. A few isolated cases have been noted in Indiana [27,
28]. Human babesiosis due to B. microti recently has been
reported from Europe while B. microti-like species have been
described as the cause of infection in people living in Asia
[13, 17, 29].
The distribution of B. microti overlaps with that of
Borrelia burgdorferi, the agent of Lyme disease, as both
organisms are transmitted by Ixodes scapularis in the United
States [19, 30]. Although the geographic distribution of
babesiosis appears to be restricted to certain foci within the
areas of endemicity for B. burgdorferi, the endemic range
is expanding. For this reason and because the number of
reported cases has dramatically increased over the last two
decades, babesiosis is recognized as an emerging infectious
disease [8, 31, 32]. The increase in incidence has often
been attributed to the expansion of the deer population
because these vertebrates are the primary host for adult ticks,
although they are not competent reservoirs for B. microti.
Other factors include better awareness of the disease by local
physicians, an encroachment of humans on wildlife habitat,
and increasing travel of immunosuppressed individuals to
endemic areas.
Although most B. microti infections are acquired by tick
bites from May through October, at least 70 patients in
the United States have acquired babesiosis by transfusion
of contaminated blood products from asymptomatic donors
[33–36]. Blood products typically are fresh or frozen packed
red blood cells, although one case has been attributed to
platelet transfusion. Several cases of neonatal babesiosis
have been reported, and these were acquired by tick bite,
transfusion, or transplacental transmission [37, 38].
2.1.2. B. duncani Infection. B. duncani is the name given
to the previously designated WA1 Babesia [3]. All nine
documented cases of B. duncani infection have occurred on
the west coast of the United States. Two people acquired the
babesial infection by transfusion of blood products while
the remaining cases were attributed to tick bites [39, 40].
One blood donor was asymptomatic at time of donation
whereas the other reported a 10-day episode of nausea. Both
recipients were immunologically at risk; one was an elderly
man and the other was a premature infant. Among the ﬁve
other symptomatic cases, one was a young normosplenic
adult living in Washington State (index case) whereas four
were splenectomized and lived in California [41, 42]. One
of these four men died. Sequence analysis of the entire 18S
rRNA gene indicated that the organisms causing babesial
illnessintheindexcasefromWashingtonStateandinthetwo
cases acquired by blood transfusion were phylogenetically
indistinguishable whereas the organisms acquired by three
of the four splenectomized cases in California formed a
separate but closely related phylogenetic group [3, 43]. The
seroprevalenceofB.duncaniinfectionhasbeenfoundtovary
from 4% to 17% [41].
2.1.3. B. divergens-Like Infection. B. divergens-like organisms
have been identiﬁed in three cases, two from the Midwest
(Missouri and Kentucky) and one from Washington State
[4, 44, 45]. All three patients had risk factors for severe
babesial disease, namely, age greater than 50 years and
splenectomy. Sequence analysis of the entire 18S rRNA gene
indicated that the Missouri isolate (MO1) and the Kentucky
isolate (KY) were identical to each other and to piroplasms
found in eastern cottontail rabbits on Nantucket Island [46].
These isolates diﬀered by a few bp in their 18S rRNA gene
from the isolate of the Washington State patient and from
the B. divergens organisms of European cattle. Because the
piroplasms isolated from eastern cottontail rabbits are not
infectious to cattle, the isolates obtained from the three US
patients are now referred to as B. divergens-like organisms.
2.2. Europe
2.2.1. B. divergens Infection. About 40 cases of B. divergens
infection have been documented in Europe, mostly from
countries with extensive cattle industry such as France, Ire-
land,andGreatBritain[47–49].Caseshavesporadicallybeen
reported from Sweden, Switzerland, Spain, Portugal, and
Croatia (index case). Nearly all patients were splenectomized
prior to the onset of Babesia infection. Because cattle are
the reservoir for B. divergens, persons at risk of contracting
babesiosis are farmers or people vacationing in rural areas.
Limited data suggest that infection with B. divergens can
be asymptomatic in normosplenic individuals [47]. There
are no reports of B. divergens infection acquired by blood
transfusion [49].
2.2.2. B. venatorum (EU1) Infection. Because the advent of
PCR allows for molecular characterization of babesial organ-
isms, a new Babesia species has been identiﬁed in Europe.
Originally referred to as EU1, the name “B. venatorum”w a s
later proposed [12]. B. venatorum, together with B. odocoilei
that infects white-tail deer in the United States, form a sister
group to that of B. divergens. Three cases of infection with
B. venatorum have been documented [12, 50]. All three were
men beyond 50 years of age who had been splenectomized.
Unlike B. divergens infections that are fulminant and often
fatal,B.venatoruminfectionshavevariedfrommildtosevere
but have not been fatal.
3.ClinicalCharacteristics
3.1. B. microti Infection. The severity of B. microti infection
is variable, depending primarily on the immune status of
the host. Several clinical syndromes have been described,
including asymptomatic infection, mild-to-moderate viral-
like illness, and severe disease with a fulminant course that
sometimes results in death or a persistent relapsing illness.
ConcurrentinfectionwithLymediseaseincreasesneitherthe
numbernorthedurationofsymptomsofbabesiosis[30,51].Interdisciplinary Perspectives on Infectious Diseases 3
It is unclear whether this is also true of concurrent babesiosis
and human granulocytic anaplasmosis.
3.1.1. Asymptomatic Infection. Following transmission of the
babesial parasite, the incubation period may last from 1 to 9
weeks [5, 8]. Many people who are infected with B. microti
never experience symptoms, as suggested by the disparity
between seroprevalence and the number of reported cases.
The frequency of asymptomatic B. microti infection was
derived from an epidemiologic study of babesiosis carried
out on Block Island, Rhode Island [6]. About a third of
babesial infections at this site were asymptomatic, including
19% (13 of 67) of adults and 40% (4 of 10) of children
[6]. Asymptomatic infection may persist for months or
years following resolution of symptomatic babesiosis [36].
It is uncertain whether patients experiencing asymptomatic
babesial infection are at risk for any long-term complica-
tions. They may transmit the infection if they donate blood
[33].
3.1.2. Mild-to-Moderate Illness. Most cases of B. microti
infection consist of a mild to moderate viral-like illness.
These cases typically begin with a gradual onset of malaise
and fatigue followed by intermittent fever and one or
more of the following: chills, sweats, headache, arthralgia,
myalgia, anorexia, cough, and nausea (Table 1)[ 30, 52–54].
Less commonly noted are gastrointestinal symptoms, weight
loss, conjunctival injection, and emotional lability [53–57].
On physical examination, fever is commonly observed and
pallor, mild splenomegaly or hepatomegaly occasionally may
be noted. The illness usually lasts for a week to months,
occasionally with prolonged recovery that can last more than
ay e a r[ 30, 36, 53, 56, 57]. Parasitemia may continue even
after the patient feels well and rarely may persist for more
than two years after the initial episode [36].
3.1.3. Severe Disease. Severe disease generally occurs in
people with underlying immunosuppressive conditions that
include HIV, malignancy, immunosuppressive medication,
and splenectomy [50, 56, 58–60]. On physical examination,
jaundice, retinal infarcts, or ecchymoses and petechiae may
be noted [55, 58, 61]. The most common complications of
severe babesiosis include acute respiratory failure, congestive
heart failure, DIC, liver and renal failure, and splenic
rupture [52]. A mortality rate of 5% was noted in a
retrospective study of 136 patients experiencing B. microti
infection on Long Island, New York, only one of whom
was known to be immunocompromised [7]. In another
study, the mortality rate among patients hospitalized for
babesiosis was 9% [52]. The mortality rate is even higher
among immunocompromised hosts. In a recent case-control
study of 14 patients who were highly immunocompromised,
21% died and the remainder experienced a prolonged,
relapsing course of illness, sometimes lasting more than
a year, despite multiple courses of standard antibabesial
therapy [59]. People 50 years of age and older also
are more likely to experience severe babesiosis [52, 54,
62].
3.2. B. duncani Infection. Although studies of infection in
hamsters suggest that B. duncani is more pathogenic than B.
microti, the small number of reported B. duncani cases does
not allow ﬁrm conclusions [32]. Of the nine reported cases
of B. duncani, one died, one experienced pulmonary edema
and renal insuﬃciency, and the remainder had a relatively
mild clinical course or were asymptomatic [3, 39, 40, 42,
63] .P a r a s i t e m i ar a n g e df r o m1 %t o5 4 % .S y m p t o m so fB.
duncani are similar to those of B. microti and consist of fever,
chills, headache, sweats, myalgia, nausea, vomiting, diarrhea,
dark urine, and fatigue.
3.3. B. divergens Infection. Nearly all 40 cases of B. divergens
infection reported in Europe had been splenectomized and
suﬀered a severe form of babesiosis [47–49]. Signs and
symptoms begin 1 to 3 weeks after tick transmission and
consist of high fever (40-41◦C) with severe intravascular
hemolysis that results in hemoglobinemia, hemoglobinuria,
and jaundice. Headache, shaking chills, intense sweating,
myalgia, and abdominal pain are common. More than half
the cases experienced a rapid onset of renal failure and
pulmonary edema. Ecchymoses, petechiae, congestive heart
failure, and coma also have been reported. The illness
generally is fulminant, lasting about a week and ending in
death in more than a third of patients or in a prolonged
convalescence.
3.4. B. venatorum (EU1) Infection. All three reported cases
of B. venatorum infection had a history of Hodgkin’s disease
andhadbeensplenectomized[12,50].Oneexperiencedmild
babesiosis, whereas two had moderate-to-severe illness. In
these two patients, babesiosis was concurrent with a relapse
of nodular lymphocyte-predominant Hodgkin’s lymphoma
or with stage IIIA diﬀuse large B cell lymphoma. All three
patients were admitted to the hospital and recovered after
antibabesial therapy. One had a prolonged relapsing illness
that eventually cleared. Peak parasitemia ranged from 1% to
30%. Symptoms included fever, dark urine, fatigue, chills,
headache, confusion, jaundice, sweats, and shortness of
breath.
4.Diagnosis
The diagnosis of babesiosis should be considered in patients
who live or travel in areas that are endemic for babesiosis
and who experience a viral-like illness in the late spring,
summer, or autumn (Table 2). As the symptoms and signs
are relatively nonspeciﬁc, laboratory testing is required
for diagnosis. In some cases, physicians may choose to
obtain screening laboratory testing such as a CBC, platelet
count, and liver enzymes before ordering speciﬁc diagnostic
tests. Most cases of babesiosis are accompanied by some
degree of hemolytic anemia with an elevated reticulocyte
count. Thrombocytopenia is common. The leukocyte count
usually is normal to slightly decreased. Elevated serum liver
enzymes occur in about half the patients. Proteinuria and
an elevated blood urea nitrogen and serum creatinine also
may be noted. Speciﬁc laboratory tests that are used for4 Interdisciplinary Perspectives on Infectious Diseases
Table 1: The most common symptoms of babesiosis caused by Babesia microti infection.
Symptom Percentage of outpatients (n = 41) Percentage of inpatients (n = 173) Percentage of all patients (n = 214)
Fever 68 89 85
Fatigue 78 79 79
Chills 39 68 63
Sweats 41 56 53
Headache 75 32 39
Myalgia 37 32 33
Anorexia 25 24 24
Cough 17 23 22
Arthralgia 31 17 18
Nausea 22 9 16
Outpatient cases are from Ruebush et al. [60] and Krause et al. [30]. Inpatient cases are from White et al. [54] and Hatcher et al. [52].
the diagnosis of babesiosis are described below. Speciﬁc
tests for concurrent Lyme disease and human granulocytic
anaplasmosis should be performed in patients presenting
with clinical manifestations that suggest coinfection, such as
an erythema migrans type rash or neutropenia.
4.1. Microscopic Identiﬁcation. Speciﬁc diagnosis of babesio-
sis can be made by microscopic identiﬁcation of the
organism using Giemsa stains of thin blood smears [64,
Figure 1].Thickbloodsmearsalsomaybeperformedbutthe
babesialorganismsaresmallandmaybediﬃculttovisualize.
B.microti and other Babesia spp. are round, oval, or pear-
shaped and have a blue cytoplasm with a red chromatin.
The ring form is most common and can be mistaken for
early stage ring forms of Plasmodium falciparum. Multiple
thin blood smears should be examined when only a few
erythrocytes are infected, particularly in the early stage
of illness when most people seek medical attention. PCR
and serology should be performed if only a few ring-like
structures are observed. Parasitemia seldom exceeds 5%
in normal hosts but may be as high as 85% in asplenic
individuals [55]. B. divergens and related organisms often
appear as paired piriforms in human red blood cells. Pairs of
B. divergens and B. divergens-like organisms are located in a
subcentral, central, or peripheral position [46]. B. venatorum
are morphologically indistinguishable from B. divergens [12,
50]. The tetrad form, referred to as a Maltese cross, is
pathognomonic of small Babesia spp. such as B. microti and
B. duncani [3]. B. duncani display more tetrad forms than B.
microti.
4.2. Polymerase Chain Reaction. The polymerase chain reac-
tion (PCR) provides a highly sensitive and speciﬁc test for
detecting Babesia DNA in blood and identiﬁes the Babesia
species [65, 66]. Rigorous precautions are required to avoid
false positive results. PCR is recommended when parasites
arenotidentiﬁedonbloodsmearsbutsymptomsandhistory
are suggestive of babesiosis. As with all Babesia speciﬁc
tests, it should only be performed in laboratories that are
experienced in such testing and meet the highest laboratory
performance standards.
Table 2: Diagnosis of babesiosis.
Epidemiology
– Residence in or travel to an area endemic for babesiosis
– Ixodes tick bite
– History of recent blood transfusion from a donor living or
traveling in a Babesia endemic area
Symptoms
– Fever, fatigue, chills, sweats, headache, myalgia, anorexia,
cough, arthralgia, nausea
– Less common: emotional lability and depression, hyper-
esthesia, sore throat, abdominal pain, conjunctival injection,
photophobia, weight loss
Signs on physical examination
–F e v e r
– Splenomegaly, hepatomegaly, pallor
Common laboratory diagnostic procedures
– Identiﬁcation of Babesia on Giemsa stained peripheral blood
smears
– Ampliﬁcation of Babesia DNA in blood using polymerase
chain reaction
–Four-fold riseinBabesiaantibodyinacute orconvalescent sera
or identiﬁcation of serum Babesia IgM antibody
4.3. Serology. Babesial infection can be conﬁrmed by sero-
logic testing using the indirect immunoﬂuorescent assay
(IFA) [67, 68]. During the acute phase of B. microti illness,
IgG titers usually exceed 1 : 1024 and decline to 1 : 64 or less
within 8 to 12 months. Thus, IgG titers of 1 : 1024 or greater
usually signify active or recent infection [69]. The detection
of IgM is indicative of recent infection [67]. Although
seroconversion occurs in virtually all immunocompetent
individuals infected with B. microti, the diagnosis of active
babesial infection based on serologic ﬁndings alone is
suspect.Serologyusuallyisnotconsideredincasesattributed
to B. divergens because the illness becomes fulminant before
antibody can be detected. Sera from patients infected with
B. divergens-like organisms or B. venatorum cross-react with
antigen from B. divergens [41, 42, 63]. Sera from patientsInterdisciplinary Perspectives on Infectious Diseases 5
Figure 1: Ring forms of B. microti revealed by Giemsa staining of a
human blood ﬁlm (magniﬁcation 1000 x).
infected with B. duncani or related organisms do not cross-
react with B. microti antigen [41, 42]. Sera from patients
infected with one of several Babesia species may cross-react
with antigen from Plasmodium species, but titers are almost
always low (1 : 16 or lower).
4.4. Ampliﬁcation of Babesia in Laboratory Animals. Babesia
parasitemiacanalsobedetectedbyinjectingpatientbloodby
the intravenous or intraperitoneal route into such laboratory
animals as hamsters or gerbils [65]. This test is only available
in a few research laboratories and is seldom useful for
diagnosis. B. microti is easily detected in hamsters whereas B.
duncani is often lethal in these animals [32]. This approach
is not suited for rapid diagnosis, as Babesia usually do not
appearinthebloodofthelaboratoryanimaluntiltwotofour
weeks after inoculation.
5. Treatment
5.1. B. microti Infection
5.1.1. Mild-to-Moderate Disease. Most people infected with
B. microti experience mild-to-moderate disease and can be
successfully treated with a combination of atovaquone and
azithromycin administered for 7 to 10 days [70, 71]. This
combination was shown to be as eﬀective as clindamycin and
quinine, the ﬁrst drug combination used in the treatment
of babesiosis. The two regimens were directly compared
in adults in a prospective, nonblinded randomized control
trial [71]. While these drug combinations were similarly
eﬀective in clearing parasitemia and achieving resolution of
symptoms, adverse eﬀects were reported in 15% of subjects
who received atovaquone and azithromycin compared with
72% of subjects who received clindamycin and quinine.
T h em o s tc o m m o ns i d ee ﬀects associated with atovaquone
and azithromycin were diarrhea and rash while those of
clindamycin and quinine were tinnitus, hearing loss, and
diarrhea. About a third of the subjects receiving clindamycin
and quinine suﬀered from adverse reactions that were severe
enough to require a decrease in dosage or discontinuing
the medication. Only 2% of subjects taking atovaquone
and azithromycin experienced such severe drug reactions.
Although the atovaquone and azithromycin combination
has not been studied in a controlled trial for pediatric use,
cure has been achieved with use of this regimen in a child
[72]. Clindamycin and quinine should be substituted for
atovaquone and azithromycin when patients do not respond
well to atovaquone and azithromycin.
5.1.2. Severe Disease. The combination of clindamycin
(administered intravenously) and quinine given for 7 to
10 days is the treatment of choice for severe babesiosis.
(Table 3)[ 70, 73]. Exchange red blood cell transfusion
is indicated for all babesiosis patients experiencing heavy
parasitemia (≥10%) or who have signiﬁcant pulmonary,
renal, or hepatic compromise [74–77]. Partial or complete
exchange transfusion rapidly decreases parasite burden and
removes toxic byproducts of Babesia infection.
5.1.3. Persistent Relapsing Disease. Babesial infection may
persist and symptoms relapse in people with signiﬁcant
underlying immunosuppression despite standard combina-
tion antimicrobial therapy [59, 77]. Atovaquone-proguanil
(250mg–100mg) was used to eradicate parasitemia in one
such patient [77]. In a recent case-control study of chronic
babesiosis in 14 highly immunocompromised patients, no
single antimicrobial combination was uniformly superior to
another in achieving resolution of infection [59]. Rather,
cure was associated with duration of therapy for a minimum
of six weeks and for at least two weeks after the last positive
bloodsmear.Interestingly,themajorityofcasepatientsinthe
study had underlying B-cell lymphoma and had been treated
with the anti-CD20 monoclonal antibody (Rituximab) prior
to acute babesial infection, thereby dramatically impairing
B-cell activity. It is important to recognize that a 7-to-10
day course of antibabesial therapy is suﬃcient for many
immunocompromised patients. Thus, when acute babesiosis
responds to a standard therapeutic course with resolution of
symptoms and clearance of parasitemia on blood smear, no
further treatment is required. Because immunosuppressed
individualsareatincreasedriskforrelapsingbabesiosis,close
clinical follow-up with repeat blood smears, Babesia PCR,
and complete blood counts should be performed.
5.1.4. Asymptomatic Infection. In the unusual event that
patients are identiﬁed with asymptomatic babesial infection,
no treatment should be given unless parasitemia, as deter-
mined by blood smear or PCR, persists for longer than three
months [70]. In this case, a one-week course of atovaquone
and azithromycin should be considered. People who have
positive serology, but negative blood smears and negative
PCR should not be treated, as they likely have resolved
the infection. Immunocompromised patients experiencing
persistent asymptomatic parasitemia should have blood
smears performed every month or two until they clear the
infection.
5.2. B. duncani Infection. Recommended treatment consists
of clindamycin and quinine [3, 39, 40, 42, 63]. Red cell6 Interdisciplinary Perspectives on Infectious Diseases
Table 3: Treatment of babesiosis.
Treatment Dose Frequency
Atovaquone and azithromycin
Atovaquone
Adult: 750mg Every 12 hours
Child: 20mg/kg Every 12 hours
(maximum 750mg/dose)
Azithromycin
Adult: 500 to 1000mg On day 1
250 to 1000mg On subsequent days
Child: 10mg/kg On day 1
(maximum 500mg/dose)
5mg/kg On subsequent days
(maximum 250mg/dose)
Clindamycin and quinine
Clindamycin
Adult: 600mg Every 8 hours
Child: 7–10mg/kg Every 6–8 hours
(maximum 600mg/dose)
Intravenous administration
Adult: 300–600mg Every 6 hours
Child: 7–10mg/kg Every 6–8 hours
(maximum 600mg/dose)
Quinine
Adult: 650mg Every 6–8 hours
Child: 8mg/kg Every 8 hours
(maximum 650mg/dose)
All antibiotics are administered by mouth unless otherwise speciﬁed. All doses are administered for 7 to 10 days except for persistent relapsing infection (see
text). For immunocompromised patients experiencing babesiosis, successful outcome has been reported using atovaquone combined with higher doses of
azithromycin (600–1000mg per day) [78].
Complete or partial exchange transfusion should be considered for treatment of severe babesiosis.
exchange transfusion should be considered in the treat-
ment of severe cases [41]. Renal insuﬃciency may require
hemodialysis.
5.3. B. divergens and B. divergens-Like Infections. The mor-
bidity and mortality rate of Babesia divergens infections are
high and any such case should be considered a medical
emergency [47, 49]. It is recommended that these infec-
tions be treated with exchange transfusion and clindamycin
and quinine. One mild case of B. divergens infection was
successfully treated with the combination of pentamidine
and trimethoprim-sulfamethoxazole whereas another only
required an abbreviated course of clindamycin and quinine
(the quinine was stopped after 4 days) [79, 80]. In both cases,
exchange transfusion was not needed. The Babesiadivergens-
like infections reported from Kentucky and Washington
State were successfully treated with clindamycin and quinine
or quinidine, but the case from Missouri died despite
clindamycin and quinine therapy [4, 44, 45].
5.4. B. venatorum Infection. Of the three cases of B. vena-
torum infection, one cleared on clindamycin alone [12,
50]. The other two were given clindamycin and quinine.
One of these patients was highly immunocompromised and
relapsedafterclindamycinandquininewasdiscontinued. He
requiredaprolongedcourseofatovaquoneandazithromycin
followed by atovaquone alone for cure. In the third case,
blood transfusion was given for massive hemolysis, and the
infection eventually cleared following antimicrobial therapy.
6. Prevention
The use of multiple strategies is most likely to be eﬀective for
prevention of babesiosis. These include personal, residential,
and community approaches [81–88]. One obvious personal
protective measure is to avoid areas where ticks, mice, and
deer are known to thrive, especially from May through
October [84]. Immunocompromised people who are at
increased risk of severe babesiosis need to avoid such
areas. Anyone who may contact foliage in endemic sites
should wear clothing that covers the lower part of the
body, tuck cuﬀs of the trousers into stockings, and spray
or impregnate clothing with permethrin (Permanone) [86].
DEET-containing products should be applied to the skin if
legs remain uncovered. After travel through a high-risk area,
a tick check should be performed and attached ticks should
be removed as soon as possible by use of tweezers [84]. No
data is available on the use of prophylactic antimicrobials
after a tick bite to prevent babesiosis nor has a human
babesiosis vaccine been developed.
Property modiﬁcations can help reduce tick exposure.
These include keeping grass mowed, removing leaf litterInterdisciplinary Perspectives on Infectious Diseases 7
at the edge of lawns, sealing stonewalls to decrease the
number of mice, using plantings that do not attract deer,
and fencing to keep deer away [84]. Acaracides can be
applied to property, rodents (Damminix or ﬁpronil), or deer
(four poster device) [82, 84, 88]. Elimination of the deer
population may sharply reduce the risk of babesiosis and
other tick-borne infections. Within 3–5 years after deer were
eliminated on Great Island oﬀ Cape Cod, Massachusetts, the
density of I. scapularis ticks fell precipitously [87]. Currently,
the Red Cross and other blood donation agencies prohibit
people with a history of babesiosis from donating blood
in order to prevent transfusion-related cases. Additional
measures such as screening blood donors for silent Babesia
infectionorinactivationofBabesiaparasitesinunitsofblood
prior to transfusion have been considered but are not yet in
use [89, 90].
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